Sign in
TerminatedPhase 4

CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 4

Key facts

Who runs it
Samsung Medical Center
Where
South Korea1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
Phase
Phase 4
People taking part
100 people enrolled
Started
17 Jan 2022
Ended
22 Mar 2024
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Type of stent
  • Duration of DAPT
Record updated
18 May 2025
Why it stopped
Ending early registration due to low registration status and lack of research

Who can take part

Age
19 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • Subject must be at least 19 years of age
  • Subject who is able to understand risks, benefits and treatment alternatives and sign informed consent voluntarily
  • Patients presenting with ACS (ST-elevation myocardial infarction [STEMI], non-ST-elevation myocardial infarction [NSTEMI], or unstable angina)
  • Patients with at least one lesion with equal or greater than 50% diameter stenosis requiring treatment with drug-eluting stents (DES) in native coronary artery or graft

Who cannot take part

  • Patients with known intolerance to aspirin, clopidogrel, prasugrel, or major components of drug-eluting stents
  • Patients who need chronic anti-coagulation therapy
  • Patients who have non-cardiac co-morbid conditions with life expectancy <1 year or that may result in protocol non-compliance (per site investigator's medical judgment)
  • Patients with active pathological bleeding
  • Patients with history of stroke or transient ischemic attack
  • Patients 75 years of age or older
  • Patients unable to provide consent
  • Pregnant or lactating women; Additional Exclusion Criteria for Antiplatelet Comparison Study:
  • Patients weighing less than 60 kg

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study is multi-center, open label, two-by-two factorial, randomized, noninferiority trial to compare the efficacy and safety of polymer-free cobalt-chromium thin drug-coated stents (BioFreedom Ultra) with biodegradable polymer ultrathin sirolimus-eluting stents (Orsiro Mission) and prasugrel monotherapy after 1-month dual antiplatelet therapy (DAPT) of aspirin plus prasugrel with 12-month DAPT of aspirin plus prasugrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

The 4 groups in the trial

  • Biodegradable Polymer DESExisting treatment, for comparison

    Patients will be randomized to either the polymer-free drug-coated stent (DCS) group or the biodegradable polymer drug-eluting (DES) group with 1:1 ratio. This group will use Orsiro Mission stent during the index procedure.

    Treatment: Type of stent

  • 12-month DAPTExisting treatment, for comparison

    Patients will be randomized to either the prasugrel monotherapy group or the 12-month dual antiplatelet therapy (DAPT) group with 1:1 ratio unless patients have additional exclusion criteria for antiplatelet study. This group will receive 12-month DAPT of aspirin (100mg once daily) plus prasugrel (10mg once daily).

    Treatment: Duration of DAPT

  • Polymer-free DCSTreatment being tested

    Patients will be randomized to either the polymer-free drug-coated stent (DCS) group or the biodegradable polymer drug-eluting (DES) group with 1:1 ratio. This group will use BioFreedom Ultra stent during the index procedure.

    Treatment: Type of stent

  • Prasugrel monotherapyTreatment being tested

    Patients will be randomized to either the prasugrel monotherapy group or the 12-month dual antiplatelet therapy (DAPT) group with 1:1 ratio unless patients have additional exclusion criteria for antiplatelet study. This group will receive aspirin (100mg once daily) plus prasugrel (10mg once daily) for 1 month and thereafter prasugrel (10mg once daily) alone.

    Treatment: Duration of DAPT

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Comparison of Polymer-Free Cobalt-Chromium Thin Drug-Coated Stents With Biodegradable Polymer Ultrathin Sirolimus-Eluting Stents and Prasugrel Monotherapy With Conventional 12-Month Dual Antiplatelet Therapy
Record updated
18 May 2025